Abstract：
Neuroendocrine tumors (NETs) are a group of well-differentiated heterogeneous neoplasms characterized by slow progression and distinct clinical and biological behavior. In the majority of patients with NET, first-line treatment is represented by somatostatin analogs (SSAs) that, despite being drugs with high tolerability (even at high doses) and providing to carcinoid symptoms control and anti-proliferative effects, may present some side effects, with potential impact on quality of life and nutritional status. The most frequent side effects are represented by gastrointestinal events in particular alterations in bowel habits (diarrhea and constipation), abdominal pain, exocrine pancreatic insufficiency, and cholelithiasis. Considering the relative rarity of NETs, literature about frequency and standard clinical management of adverse events SSA-related is still lacking and heterogeneous. The aim of this review is to arm gastroenterologists and other physicians treating NET patients with essential knowledge on the side effects of SSAs. By identifying and managing these adverse events early, healthcare professionals can offer optimal care, avert foreseeable complications, and ensure the best outcomes for patients. Without such early recognition, there is a risk of diminishing the patient\'s quality of life and their ability to sustain treatment over time.
摘要：
神经内分泌肿瘤（NETs）是一组分化良好的异质性肿瘤，其特征是进展缓慢，临床和生物学行为不同。在大多数NET患者中，一线治疗以生长抑素类似物(SSAs)为代表，尽管药物具有高耐受性（即使在高剂量），并提供类癌症状控制和抗增殖作用，可能会出现一些副作用，对生活质量和营养状况有潜在影响。最常见的副作用表现为胃肠道事件，特别是排便习惯的改变（腹泻和便秘）。腹痛,胰腺外分泌功能不全，和胆石症.考虑到NET的相对稀有性，有关SSA相关不良事件发生频率和标准临床管理的文献尚缺乏,且存在异质性.这篇综述的目的是让胃肠病学家和其他治疗NET患者的医生了解SSA副作用的基本知识。通过及早识别和管理这些不良事件，医疗保健专业人员可以提供最佳护理，避免可预见的并发症，并确保患者的最佳结果。没有这么早的认识,随着时间的推移，患者的生活质量和维持治疗的能力有降低的风险。
